Teresa A Simon1,2, Lixian Dong3, Kevin L Winthrop4. 1. Bristol Myers Squibb, Princeton, NJ, 08543, USA. teresa.simon1@verizon.net. 2. Current affiliation: Physicians Research Center, LLC, Toms River, NJ, 08753, USA. teresa.simon1@verizon.net. 3. Bristol Myers Squibb, Princeton, NJ, 08543, USA. 4. Oregon Health & Science University, Portland, 97239, OR, USA.
Abstract
BACKGROUND: To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials. METHODS: This pooled analysis of 16 randomized, double-blind/open-label trials, with ≥ 1 abatacept (intravenous or subcutaneous) arm, and with/without placebo control covered cumulative (controlled short-term and open-label long-term) abatacept exposure periods. OIs were analyzed separately in controlled (abatacept and placebo individually) and cumulative periods. OIs were identified using a prespecified list; events were independently adjudicated. Unadjusted incidence rates (IRs; per 100 patient-years) with 95% confidence intervals (CIs) were calculated. RESULTS: In cumulative periods, 7044 patients received abatacept, with a mean (standard deviation) duration of exposure of 36.9 (26.2) months (21,274 patient-years of exposure). IRs (95% CIs) of OIs were 0.17 (0.05-0.43) for abatacept and 0.56 (0.22-1.15) for placebo during the controlled periods and 0.21 (0.15-0.28) for abatacept during the cumulative periods. There was 1 case of tuberculosis in both the abatacept (IR [95% CI] 0.04 [0.00-0.24]) and placebo (IR [95% CI] 0.08 [0.00-0.44]) groups during the controlled periods; 13 verified tuberculosis cases (IR [95% CI] 0.06 [0.03-0.10]) were reported in the cumulative period. Herpes zoster was reported numerically more often with abatacept (IR 1.9 [1.4-2.5]), versus placebo (1.7 [1.1-2.6]) in the controlled periods; within the cumulative period, herpes zoster IR (95% CI) was 1.53 (1.36-1.71) for abatacept-treated patients. CONCLUSION: In controlled periods of the clinical trials, abatacept-treated patients had similarly low rates of OIs compared with placebo-treated patients. Overall, OI rates were similar among abatacept-treated patients in the controlled and cumulative periods and consistent with the ranges reported in the literature.
RCT Entities:
BACKGROUND: To evaluate incidence of opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with abatacept in clinical trials. METHODS: This pooled analysis of 16 randomized, double-blind/open-label trials, with ≥ 1 abatacept (intravenous or subcutaneous) arm, and with/without placebo control covered cumulative (controlled short-term and open-label long-term) abatacept exposure periods. OIs were analyzed separately in controlled (abatacept and placebo individually) and cumulative periods. OIs were identified using a prespecified list; events were independently adjudicated. Unadjusted incidence rates (IRs; per 100 patient-years) with 95% confidence intervals (CIs) were calculated. RESULTS: In cumulative periods, 7044 patients received abatacept, with a mean (standard deviation) duration of exposure of 36.9 (26.2) months (21,274 patient-years of exposure). IRs (95% CIs) of OIs were 0.17 (0.05-0.43) for abatacept and 0.56 (0.22-1.15) for placebo during the controlled periods and 0.21 (0.15-0.28) for abatacept during the cumulative periods. There was 1 case of tuberculosis in both the abatacept (IR [95% CI] 0.04 [0.00-0.24]) and placebo (IR [95% CI] 0.08 [0.00-0.44]) groups during the controlled periods; 13 verified tuberculosis cases (IR [95% CI] 0.06 [0.03-0.10]) were reported in the cumulative period. Herpes zoster was reported numerically more often with abatacept (IR 1.9 [1.4-2.5]), versus placebo (1.7 [1.1-2.6]) in the controlled periods; within the cumulative period, herpes zoster IR (95% CI) was 1.53 (1.36-1.71) for abatacept-treated patients. CONCLUSION: In controlled periods of the clinical trials, abatacept-treated patients had similarly low rates of OIs compared with placebo-treated patients. Overall, OI rates were similar among abatacept-treated patients in the controlled and cumulative periods and consistent with the ranges reported in the literature.
Authors: Pablo A Olivera; Juan S Lasa; Stefanos Bonovas; Silvio Danese; Laurent Peyrin-Biroulet Journal: Gastroenterology Date: 2020-01-09 Impact factor: 22.682
Authors: Bee Eng Tan; Ai Lee Lim; Sow Lai Kan; Chong Hong Lim; Esther Ee Ling Tsang; Shereen Suyin Ch'ng; Nadiah Mohd Noor; Nurulraziquin Mohd Jamid; Cheng Lay Teh; Rachel Joshua Thundyil; Yet Lin Loh; Hwee Cheng Chong; Swee Gaik Ong; Asmahan Mohamed Ismail; Yvonne Y L Lee; Suk Chyn Gun Journal: Rheumatol Int Date: 2017-07-10 Impact factor: 2.631
Authors: John W Baddley; Kevin L Winthrop; Lang Chen; Liyan Liu; Carlos G Grijalva; Elizabeth Delzell; Timothy Beukelman; Nivedita M Patkar; Fenglong Xie; Kenneth G Saag; Lisa J Herrinton; Daniel H Solomon; James D Lewis; Jeffrey R Curtis Journal: Ann Rheum Dis Date: 2013-07-13 Impact factor: 19.103
Authors: Teresa A Simon; Johan Askling; Diane Lacaille; Jarrod Franklin; Frederick Wolfe; Allison Covucci; Samy Suissa; Marc C Hochberg Journal: Arthritis Res Ther Date: 2010-04-14 Impact factor: 5.156
Authors: M C Genovese; M Schiff; M Luggen; J-C Becker; R Aranda; J Teng; T Li; N Schmidely; M Le Bars; M Dougados Journal: Ann Rheum Dis Date: 2007-10-05 Impact factor: 19.103
Authors: Teresa A Simon; Benjamin P Soule; Marc Hochberg; Douglas Fleming; Anne Torbeyns; Subhashis Banerjee; Maarten Boers Journal: ACR Open Rheumatol Date: 2019-05-29
Authors: H K Genant; C G Peterfy; R Westhovens; J-C Becker; R Aranda; G Vratsanos; J Teng; J M Kremer Journal: Ann Rheum Dis Date: 2007-12-17 Impact factor: 19.103